Miraculous breast cancer vaccine passes first human trials that went on for 20 years
Excerpt from the Press Release:
A team of researchers at the University of Washington School of Medicine (UWSM) has been working on a breast cancer vaccine for over the last 20 years. In their recently published study, they finally revealed the results of the phase one human trials of their breast cancer vaccine.
A WHO report suggests that currently, over seven million women suffer from breast cancer, making it one of the deadliest cancers across the globe. In 2022 alone, 43,550 female and 530 male patients (yes, men can also have breast cancer, it is rare, though) in the US could die because of breast cancer, according to the National Breast Cancer Foundation. However, the research work from UWSM hints that soon we might be able to control the disease.
During the phase one trials, the experimental breast cancer vaccine has proved to be safe and highly effective in preventing the growth of human epidermal growth receptor 2 (HER2) cancer tumor cells.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?